Get Premium to unlock powerful stock data
NAS:FHTX (USA)  
Foghorn Therapeutics Inc logo

Foghorn Therapeutics Inc

$ 14.54 -0.06 (-0.41%) 10:09 PM EST
P/E:
At Loss
P/B:
8.32
Market Cap:
$ 602.94M
Enterprise V:
$ 237.27M
Volume:
73.50K
Avg Vol (2M):
190.97K
Volume:
73.50K
Market Cap $:
602.94M
PE Ratio:
At Loss
Avg Vol (2-Month):
190.97K
Enterprise Value $:
237.27M
PB Ratio:
8.32
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Foghorn Therapeutics Inc
NAICS : 541714 SIC : 2833
500 Technology Square, Suite 700, Cambridge, MA, USA, 02139
Description
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Name Current Vs Industry Vs History
Cash-To-Debt 7.51
Equity-to-Asset 0.15
Debt-to-Equity 0.78
Debt-to-EBITDA -0.56
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.28
Distress
Grey
Safe
Beneish M-Score -0.48
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -25.7
3-Year EPS without NRI Growth Rate -26.7
3-Year FCF Growth Rate -5.4

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 70.94
9-Day RSI 62.89
14-Day RSI 58.99
6-1 Month Momentum % -27.17
12-1 Month Momentum % 29.86

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.91
Quick Ratio 8.91
Cash Ratio 8.8
Days Sales Outstanding 22107.81

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -28.1

Financials (Next Earnings Date:2022-08-10 Est.)

FHTX's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:FHTX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 4.953
EPS (TTM) ($) -2.76
Beta 0
Volatility % 138.9
14-Day RSI 58.99
14-Day ATR ($) 1.130459
20-Day SMA ($) 13.476
12-1 Month Momentum % 29.86
52-Week Range ($) 8.01 - 24.34
Shares Outstanding (Mil) 41.47

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Foghorn Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More